The Fight Against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
TREA analyzes over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: FDA (Food and Drug Administration), NIH (National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2 among others.
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| The Fight Against COVID19 | -1.68% | - | - | - |
| ^GSPC | -0.04% | +2.42% | +23.76% | +5740.43% |
14 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 145.54 | +0.09 | +0.06% | 4:00 p.m. EDT | 4.08M | 7.52M | 350.27B |
| ABBV | AbbVie Inc. | 168.59 | +2.03 | +1.22% | 4:00 p.m. EDT | 4.38M | 5.32M | 297.71B |
| PFE | Pfizer Inc. | 27.53 | -0.12 | -0.43% | 4:00 p.m. EDT | 29.46M | 38.10M | 156.00B |
| SNY | Sanofi | 46.25 | -1.28 | -2.69% | 4:00 p.m. EDT | 3.80M | 2.18M | 118.92B |
| REGN | Regeneron Pharmaceuticals, Inc. | 1036.52 | +9.97 | +0.97% | 4:00 p.m. EDT | 353.92k | 426.58k | 114.21B |
| GSK | GSK plc | 40.65 | -0.46 | -1.12% | 4:00 p.m. EDT | 2.24M | 3.38M | 84.02B |
| GILD | Gilead Sciences, Inc. | 65.06 | +2.27 | +3.62% | 4:00 p.m. EDT | 9.32M | 6.91M | 81.05B |
| MRNA | Moderna, Inc. | 140.03 | -5.20 | -3.58% | 4:00 p.m. EDT | 3.60M | 3.87M | 53.67B |
| TAK | Takeda Pharmaceutical Company Limited | 13.1 | +0.02 | +0.15% | 4:00 p.m. EDT | 1.07M | 1.56M | 41.36B |
| BNTX | BioNTech SE | 92.08 | -3.92 | -4.08% | 4:00 p.m. EDT | 768.30k | 735.39k | 22.19B |
| NVAX | Novavax, Inc. | 14.4 | -0.65 | -4.32% | 4:00 p.m. EDT | 17.33M | 14.81M | 2.12B |
| VIR | Vir Biotechnology, Inc. | 9.75 | -0.61 | -5.89% | 4:00 p.m. EDT | 1.38M | 987.00k | 1.33B |
| INO | Inovio Pharmaceuticals, Inc. | 9.09 | -0.36 | -3.81% | 4:00 p.m. EDT | 230.16k | 342.36k | 235.53M |
Business WireTakeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
OSAKA, Japan & CAMBRIDGE, Mass., June 17, 2024--Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies.
Clinical Trials ArenaJohnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial
Nipocalimab offered a statistically significant and clinically meaningful improvement in the ClinESSDAI score versus placebo.
Pharmaceutical TechnologyNovavax seeks FDA approval for updated Covid-19 vaccine
The JN.1 vaccine demonstrated broad cross-neutralising antibodies effective against various variant strains.
Sign in to view your followed lists
© 2024 Yahoo. All rights reserved.